Free Trial
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals logo
$16.78 -0.12 (-0.71%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$16.78 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Key Stats

Today's Range
$16.71
$17.18
50-Day Range
$13.01
$16.97
52-Week Range
$9.57
$30.41
Volume
800,545 shs
Average Volume
1.55 million shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.71
Consensus Rating
Moderate Buy

Company Overview

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

ARWR MarketRank™: 

Arrowhead Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 209th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Arrowhead Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arrowhead Pharmaceuticals is -11.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arrowhead Pharmaceuticals is -11.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Arrowhead Pharmaceuticals has a PEG Ratio of 19.75. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Arrowhead Pharmaceuticals has a P/B Ratio of 10.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arrowhead Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.59% of the float of Arrowhead Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arrowhead Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.59% of the float of Arrowhead Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.
  • News Sentiment

    Arrowhead Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Arrowhead Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $989,735.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arrowhead Pharmaceuticals' insider trading history.
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

ARWR Arrowhead Pharmaceuticals, Inc. - Seeking Alpha
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Headlines

ARWR Stock Analysis - Frequently Asked Questions

Arrowhead Pharmaceuticals' stock was trading at $18.80 on January 1st, 2025. Since then, ARWR shares have decreased by 10.7% and is now trading at $16.78.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Monday, May, 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The biotechnology company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million.
Read the conference call transcript
.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

Last Earnings
5/12/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARWR
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.71
High Stock Price Target
$80.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+160.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
19.75
Net Income
-$599.49 million
Pretax Margin
-27.93%

Debt

Sales & Book Value

Annual Sales
$3.55 million
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
10.90

Miscellaneous

Free Float
132,162,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
0.93

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ARWR) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners